Protocol Ledger

NCT07067463 · Phase III · RECRUITING

A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

Interventional Phase III clinical trial protocol NCT07067463 sponsored by Zenas BioPharma (USA) in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-23 Enrollment: 705 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07067463
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)705 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07067463
Protocol FieldVerified Registry Value
NCT IdentifierNCT07067463
Consolidated Lead SponsorZenas BioPharma (USA)
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment705 participants (ESTIMATED)
Registered Start Date2026-03-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07067463
Hospital Research SiteLocationSite Profile
University of Kansas Medical CenterKansas City, KSOpen Hospital Dossier ->
Washington University and Siteman Cancer CenterSaint Louis, MOOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI